Pfizer will end the global development of its bleeding disorder gene therapy, Beqvez. This decision marks a discontinuation of the program, which was aimed at treating hemophilia B.
The cessation of development for Beqvez represents a pipeline setback for Pfizer in the gene therapy segment. This move impacts the company's future offerings in the rare disease space.
The company had previously received regulatory approvals for Beqvez in the U.S. and EU. However, the decision to end global development indicates a strategic re-evaluation of the asset's potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.